Ischemia is the condition where blood flow to a tissue is stopped. The restriction in blood flow causes the tissue to become necrotic. Ischemia-related tissue injury could occur in various organs. In heart, ischemia results in myocardial infarction (heart attack). Ischemia to the brain is known as cerebral ischemia and can result in stroke. If blood flow to the ischemic area is restored within a very short interval significant tissue damage can be prevented. Longer time intervals often lead to irreversible organ damage. Under conditions of blood circulation restoration, an event known as reperfusion injury occurs. During reperfusion injury, inflammatory responses occur including recruitment of inflammatory cells, vascular leakage, release of free radicals, and proteins that cause tissue destruction. No drug can prevent this unmet need.
There are no currently available drug therapies but surgeries are available to remove the blood clot responsible for restricted blood flow.
NovelMed is developing monoclonal antibodies (MoAbs) for the treatment of ischemia-reperfusion injury. The drug inhibits neutrophil activation, monocyte activation, platelet activation,and formation of leukocyte-platelet aggregates. This unique molecule also posseses anti-inflammatory properties. NovelMed is investigating the application of its lead candidate for the treatment of Ischemia Reperfusion Injury. The molecule is planned to be evaluated in multiple I/R animal models prior to IND filings.